Nutriband Receives Notice of Allowance from CNIPA for AVERSA™ Patent Application

Introduction

Nutriband Inc., a company specializing in prescription transdermal pharmaceutical products, has recently announced that it has received a Notice of Allowance from the Chinese National Intellectual Property Administration (CNIPA) for its patent application covering the AVERSA™ abuse deterrent transdermal technology. This innovative technology utilizes a proprietary aversive agent coating to prevent the abuse and accidental exposure of transdermal opioid and stimulant patch products.

Overview of AVERSA™ Technology

The AVERSA™ abuse deterrent transdermal technology developed by Nutriband consists of a unique aversive agent coating that leverages taste aversion to discourage the oral abuse of transdermal patches. This technology has the potential to revolutionize the pharmaceutical industry by offering a safer alternative for patients in need of opioid and stimulant medication.

Global Impact

With patents issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, Mexico, Canada, Australia, and now China, Nutriband’s AVERSA™ technology is poised to make a significant impact on a global scale. This broad international intellectual property portfolio ensures that the technology is protected and can be widely adopted to benefit patients worldwide.

Implications for Individuals

For individuals, the availability of AVERSA™ abuse deterrent transdermal patches such as AVERSA Fentanyl can provide peace of mind knowing that there are measures in place to prevent abuse and accidental exposure to potent medications. This technology has the potential to improve patient safety and reduce the risk of misuse, ultimately leading to better health outcomes for those in need of opioid and stimulant therapy.

Implications for the World

On a global scale, the introduction of Nutriband’s AVERSA™ technology has the potential to change the landscape of prescription transdermal pharmaceuticals by setting a new standard for abuse-deterrent products. This advancement in pharmaceutical technology underscores the importance of prioritizing patient safety and combating the opioid crisis on a worldwide level.

Conclusion

In conclusion, Nutriband’s receipt of a Notice of Allowance from CNIPA for its AVERSA™ patent application marks a significant milestone in the development of abuse deterrent transdermal technology. With the potential to be the world’s first and only abuse-deterrent opioid patch, AVERSA Fentanyl represents a major step forward in ensuring the safe and effective delivery of opioid and stimulant medications to patients in need.